New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
05:52 EDTREGNRegeneron upgraded to Buy from Neutral at Citigroup
Citigroup upgraded it rating on Regeneron (REGN) to Buy from Neutral after its survey of retinal surgeons indicated the company's Eylea drug will beat estimates over the near and long term. Citi also believes Regeneron's pipeline is not adequately reflected in the current share price. The firm raised its price target for the stock to $390 from $342. Shares of Regeneron closed Friday up $1.43 to $329.50.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
07:57 EDTREGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 11, 2014
07:07 EDTREGNRegeneron reports Q2 EPS 9c, consensus 6c
Subscribe for More Information
05:32 EDTREGNRegeneron Eylea injection receives EU approval for DME treatment
Subscribe for More Information
August 7, 2014
17:12 EDTREGNRegeneron reports 8.1% passive stake in Avalanche Biotechnologies
Subscribe for More Information
August 6, 2014
08:40 EDTREGNRegeneron price target raised to $373 from $349 at RBC Capital
RBC Capital increased its price target on Regeneron as the firm thinks that the company's Q2 results addressed many of investors' concerns. The firm is upbeat on the company's near-term outlook and keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use